Serological responses to vaccination in children exposed in utero to ustekinumab or vedolizumab: cross-sectional analysis of a prospective multicentre cohort.
Biologic treatment
Inflammatory bowel disease
Pregnancy
Prenatal exposure
Vaccination
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
18 Jul 2024
18 Jul 2024
Historique:
received:
05
03
2024
accepted:
05
07
2024
revised:
02
07
2024
medline:
18
7
2024
pubmed:
18
7
2024
entrez:
18
7
2024
Statut:
aheadofprint
Résumé
Evidence on serological responses to vaccination in children exposed to ustekinumab (UST) or vedolizumab (VDZ) in utero is lacking. This multicentre prospective study aimed to assess the impact of prenatal exposure to UST or VDZ due to maternal inflammatory bowel disease (IBD) on serological responses to vaccination and other immunological parameters in exposed children. Children aged ≥ 1 year who were exposed in utero to UST or VDZ and completed at least 1-year of mandatory vaccination were included. We assessed the serological response to vaccination (non-live: tetanus, diphtheria, and Haemophilus influenzae B; live: mumps, rubella, and measles), whole blood count, and immunoglobulin levels. The control group comprised unexposed children born to mothers without IBD. A total of 23 children (median age, 25 months) exposed to UST (n = 13) or VDZ (n = 10) and 10 controls (median age, 37 months) were included. The serological response to vaccination was comparable between the UST and VDZ groups and controls, with an adequate serological response rate of ≥ 80%. Only children exposed to UST showed a slightly reduced serological response to mumps (67% vs. 86% in controls), whereas all children exposed to VDZ showed an adequate response. The majority of the exposed children had normal levels of individual immunoglobulin classes, similar to the controls. No severe pathology was observed in any of the children.Conclusion: Despite the limited sample size, our findings suggest that in utero exposure to VDZ or UST does not significantly impair the vaccine response or broader immunological parameters in exposed children.
Identifiants
pubmed: 39023645
doi: 10.1007/s00431-024-05683-4
pii: 10.1007/s00431-024-05683-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Torres J, Chaparro M, Julsgaard M et al (2023) European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation. J Crohns Colitis 17(1):1–27. https://doi.org/10.1093/ecco-jcc/jjac115
doi: 10.1093/ecco-jcc/jjac115
pubmed: 36005814
Wieringa JW, van der Woude CJ (2020) Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. Best Pract Res Clin Gastroenterol 44–45:101665. https://doi.org/10.1016/j.bpg.2019.101665
doi: 10.1016/j.bpg.2019.101665
pubmed: 32359679
Duricova D, Dvorakova E, Hradsky O et al (2019) Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation. Inflamm Bowel Dis 25(4):789–796. https://doi.org/10.1093/ibd/izy294
doi: 10.1093/ibd/izy294
pubmed: 30239799
Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U (2018) Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 16(1):99–105. https://doi.org/10.1016/j.cgh.2017.08.041
doi: 10.1016/j.cgh.2017.08.041
de Lima A, Kanis SL, Escher JC, van der Woude CJ (2018) Hepatitis B vaccination effective in children exposed to anti-tumour necrosis factor alpha in utero. J Crohns Colitis 12(8):948–953. https://doi.org/10.1093/ecco-jcc/jjy053
doi: 10.1093/ecco-jcc/jjy053
pubmed: 29726943
Gisbert JP, Chaparro M (2023) Vaccines in children exposed to biological agents in utero and/or during breastfeeding: are they effective and safe? J Crohns Colitis 17(6):995–1009. https://doi.org/10.1093/ecco-jcc/jjad005
doi: 10.1093/ecco-jcc/jjad005
pubmed: 36652274
Wyant T, Leach T, Sankoh S et al (2015) Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 64(1):77–83. https://doi.org/10.1136/gutjnl-2014-307127
doi: 10.1136/gutjnl-2014-307127
pubmed: 24763133
Brodmerkel C, Wadman E, Langley RG et al (2013) Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol JDD 12(10):1122–1129
pubmed: 24085047
Haykir Solay A, Eser F (2019) High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study. Hum Vaccines Immunother 15(5):1177–1182. https://doi.org/10.1080/21645515.2019.1574151
doi: 10.1080/21645515.2019.1574151
Mitrova K, Pipek B, Bortlik M et al (2022) Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study. J Crohns Colitis 16(12):1808–1815. https://doi.org/10.1093/ecco-jcc/jjac086
doi: 10.1093/ecco-jcc/jjac086
pubmed: 35708729
https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByCountry?SelectedCountryId=201&IncludeChildAgeGroup=true&IncludeChildAgeGroup=false&IncludeAdultAgeGroup=true&IncludeAdultAgeGroup=false . Accessed 2 Jul 2024
Pittet LF, Verolet CM, Michetti P et al (2019) High immunogenicity of the pneumococcal conjugated vaccine in immunocompromised adults with inflammatory bowel disease. Am J Gastroenterol 114(7):1130–1141. https://doi.org/10.14309/ajg.0000000000000289
doi: 10.14309/ajg.0000000000000289
pubmed: 31205131
Moses J, Alkhouri N, Shannon A et al (2012) Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol 107(1):133–138. https://doi.org/10.1038/ajg.2011.295
doi: 10.1038/ajg.2011.295
pubmed: 21876562
Nguyen DL, Nguyen ET, Bechtold ML (2015) Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci 60(8):2446–2453. https://doi.org/10.1007/s10620-015-3631-y
doi: 10.1007/s10620-015-3631-y
pubmed: 25796579
Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M (2012) Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 107(10):1460–1466. https://doi.org/10.1038/ajg.2012.79
doi: 10.1038/ajg.2012.79
pubmed: 23034605
Jiang HY, Wang SY, Deng M et al (2017) Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine 35(20):2633–2641. https://doi.org/10.1016/j.vaccine.2017.03.080
doi: 10.1016/j.vaccine.2017.03.080
pubmed: 28404358
Fitzpatrick T, Alsager K, Sadarangani M et al (2023) Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. Lancet Child Adolesc Health 7(9):648–656. https://doi.org/10.1016/S2352-4642(23)00136-0
doi: 10.1016/S2352-4642(23)00136-0
pubmed: 37390832
Moens A, van der Woude CJ, Julsgaard M et al (2020) Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther 51(1):129–138. https://doi.org/10.1111/apt.15539
doi: 10.1111/apt.15539
pubmed: 31692017
Rowan CR, Cullen G, Mulcahy HE et al (2018) Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohns Colitis 12(3):376–378. https://doi.org/10.1093/ecco-jcc/jjx141
doi: 10.1093/ecco-jcc/jjx141
pubmed: 29045603
Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R (2019) Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn’s disease. J Crohns Colitis 13(2):267–269. https://doi.org/10.1093/ecco-jcc/jjy153
doi: 10.1093/ecco-jcc/jjy153
pubmed: 30388211
Mitrova K, Pipek B, Bortlik M et al (2021) Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study. Ther Adv Gastroenterol 14:17562848211032790. https://doi.org/10.1177/17562848211032790
doi: 10.1177/17562848211032790
Saito J, Kaneko K, Kawasaki H et al (2022) Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum. J Pharm Health Care Sci 8(1):18. https://doi.org/10.1186/s40780-022-00249-8
doi: 10.1186/s40780-022-00249-8
pubmed: 35773736
pmcid: 9248188
Mahadevan U, Long MD, Kane SV et al (2021) Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology 160(4):1131–1139. https://doi.org/10.1053/j.gastro.2020.11.038
doi: 10.1053/j.gastro.2020.11.038
pubmed: 33227283
Julsgaard M, Baumgart DC, Baunwall SMD et al (2021) Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. Aliment Pharmacol Ther 54(10):1320–1329. https://doi.org/10.1111/apt.16593
doi: 10.1111/apt.16593
pubmed: 34472644
Flanagan E, Gibson PR, Wright EK et al (2020) Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther 52(10):1551–1562. https://doi.org/10.1111/apt.16102
doi: 10.1111/apt.16102
pubmed: 32981127
Flanagan E, Prentice R, Wright EK et al (2022) Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Aliment Pharmacol Ther 55(6):700–704. https://doi.org/10.1111/apt.16739
doi: 10.1111/apt.16739
pubmed: 34907546
Wieringa JW, van Beek RHT, Rövekamp LW, Driessen GJA, van Wering HM (2021) Response to vaccination in infants exposed to antitumor necrosis factor alpha in utero. Pediatr Infect Dis J 40(10):912–916. https://doi.org/10.1097/INF.0000000000003271
doi: 10.1097/INF.0000000000003271
pubmed: 34260494
Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U (2016) The effect of maternal peripartum anti-TNFα use on infant immune response. Dig Dis Sci 61(6):1622–1627. https://doi.org/10.1007/s10620-015-3992-2
doi: 10.1007/s10620-015-3992-2
pubmed: 26725061
Hefele L, Lai J, Vilivong K et al (2022) Haemophilus influenzae serotype b seroprevalence in central Lao PDR before and after vaccine introduction. PLoS ONE 17(9):e0274558. https://doi.org/10.1371/journal.pone.0274558
doi: 10.1371/journal.pone.0274558
pubmed: 36107979
pmcid: 9477263
Zinke M, Disselhoff J, DTP a-HBV-IPV-110 and -111 study groups, Gartner B, Jacquet JM (2010) Immunological persistence in 4–6 and 7–9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vaccin 6(2):189–193. https://doi.org/10.4161/hv.6.2.10117
doi: 10.4161/hv.6.2.10117
pubmed: 20009522